Review
Open access
Sep 2026
Safety-guided selection of CDK4/6 inhibitors in HR+/HER2− metastatic breast cancer: toxicity profiles, dose modification, and clinical risk–benefit considerations
CDK4/6i selection should therefore be individualized according to toxicity profile, comorbidities, monitoring feasibility, and patient preference, with cautious interpretation of indirect comparative and real-world evidence.
Nidhi Shrivastava, Santhosh L. Gaonkar, Fayaz Shaik Mahammad
· Therapeutic Advances in Drug... · 0 citations